• Vivos filed an Early Feasibility Investigational Device Exemption application with the FDA for RadioGel Precision Radionuclide Therapy.
• FDA feedback or a decision is expected within the standard 30-day review period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050830PRIMZONEFULLFEED9732301) on June 05, 2026, and is solely responsible for the information contained therein.